References
- Zimmermann-Górska I. [Choroby związane z obecnością kryształów]. In: Gajewski P, et al. eds. [Interna Szczeklika], 2014, 1st ed. Warsaw, Poland: Medycyna Praktyczna; 2014:1929–1933.
- Ryu ES, Kim MJ, Shin HS, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol. 2013;304:F471–F480.
- Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642–650.
- Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol. 2012;36:324–331.
- Internet site: http://rarerenal.org/clinician-information/adtkd-clinician-information/
- Raciborski F, ed. [Występowanie i leczenie dny moczanowej w Polsce. Analiza, wskazania, rekomendacje]. Raport Instytutu Ochrony Zdrowia. Instytut Ochrony Zdrowia, 2015.
- Alaygut D, Torun-Bayram M, Soylu A, Kasap B, Türkmen M, Kavukçu S. Chronic kidney disease in an adolescent with hyperuricemia: Familial juvenile hyperuricemic nephropathy. Turk J Pediatr. 2013;55:637–640.
- Lee DH, Kim JK, Oh SE, Noh JW, Lee YK. A case of familial juvenile hyperuricemic nephropathy with novel uromodulin gene mutation, a novel heterozygous missense mutation in Korea. J Korean Med Sci. 2010;25:1680–1682.
- Moskowitz JL, Piret SE, Lhotta K, et al. Association between genotype and phenotype in uromodulin-associated kidney disease. Clin J Am Soc Nephrol. 2013;8:1349–1357.
- Lhotta K, Piret SE, Kramar R, Thakker RV, Sunder-Plassmann G, Kotanko P. Epidemiology of uromodulin-associated kidney disease – results from a nation-wide survey. Nephron Extra. 2012;2:147–158.
- Levy GD, Rashid N, Niu F, Cheetham TC. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol. 2014;41:955–962.
- Fairbanks LD, Cameron JS, Venkat-Raman G, et al. Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease. QJM. 2002;95:597–607.
- Cameron JS, Moro F, Simmonds HA. Gout, uric acid and purine metabolism in paediatric nephrology. Pediatr Nephrol. 1993;7:105–118.